Skip to content

Aura Biosciences, Inc. AURA Book value per share

Book value per share at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$33.20+3.0%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
-$0.85-22.2%
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
$10.57-8.8%
CG Oncology logo
CG OncologyCGON
$12.92+39.6%
Relmada Therapeutics, Inc. logo
Relmada Therapeutics, Inc.RLMD
$2.53+242%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
-$1.35-122%

Other financials

Income statement

See full
Operating income-$34.9M-20.1%
Net income-$33.7M-22.6%
EPS (diluted)-$0.50+9.1%

Balance sheet

See full
Cash & equivalents$84.8M+122%
Total debt$17.0M-7.9%
Total equity$107.2M-16.2%
Total assets$137.7M-11.4%

Cash flow

See full
Operating cash flow-$29.9M-28.0%
CapEx$102.0K-45.5%
Free cash flow-$30.0M-27.4%

Valuation

See full
Market cap$709.23M+89.4%
Enterprise value$641.43M+80.8%

Returns & leverage

See full
Return on equity-95.6%+222pp
Debt / equity0.2×0.0×
Current ratio7.1×-4.0×

Where this comes from

Calculated from Aura Biosciences, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Aura Biosciences, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aura Biosciences, Inc.'s book value per share.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Aura Biosciences, Inc.'s book value per share?
Aura Biosciences, Inc. (AURA) reported book value per share of $1.59 in Q1 2026.
How has Aura Biosciences, Inc.'s book value per share changed year-over-year?
Aura Biosciences, Inc.'s book value per share decreased by 37.7% year-over-year, from $2.55 to $1.59.
What is the long-term trend for Aura Biosciences, Inc.'s book value per share?
Over 5 years (2020 to 2025), Aura Biosciences, Inc.'s book value per share has grown at a -62.3% compound annual growth rate (CAGR), from -$296.06 to $2.27.
What does book value per share mean?
Shareholders' equity divided by diluted shares outstanding at the quarter end. The accounting (book) value attributable to each share.